Investment Highlights
Leader in the development of isoflavonoid-based therapeutics, an emerging field of drug development
- Novel family of G-protein inhibitors blocking key signaling pathways
- Key proprietary know-how on maximizing drug-like activity
Targeted applications across multiple therapeutic areas of high unmet need, including cancer, cardiovascular disease, neurodegenerative disease and autoimmune diseases
Commencing with Veyonda®, a sphingosine kinase inhibitor that boosts tumor response to chemotherapy and radiotherapy, major unmet needs
Targeting 2022 for revenue generation through commercialization of Veyonda® in first instance as radio-enhancer
Seasoned management and Board with deep public-company biotechnology experience
- Founder and CEO, Graham Kelly, previously founded NASDAQ-listed companies - Novogen Ltd and Marshall Edwards Inc (MEI Pharma Inc).
To view Presentation please download PDF attached:
Download this document
